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Key Points
• Mobilized hematopoietic
stem cells transduced with
IV injected HD-Ad5/3511
vectors home to the
BM persist long term.
• Our approach allows for the
stable genetic modification of
primitive, long-term persisting
HSPCs.
Current protocols for hematopoietic stem/progenitor cell (HSPC) gene therapy, involving
the transplantation of ex vivo genetically modified HSPCs are complex and not without
risk for the patient. We developed a new approach for in vivo HSPC transduction that
does not require myeloablation and transplantation. It involves subcutaneous injec-
tions of granulocyte-colony-stimulating factor/AMD3100 to mobilize HSPCs from the
bonemarrow (BM) into the peripheral blood stream and the IV injection of an integrating,
helper-dependent adenovirus (HD-Ad5/3511) vector system. These vectors target CD46,
a receptor that is uniformly expressed on HSPCs. We demonstrated in human CD46
transgenic mice and immunodeficient mice with engrafted human CD341 cells that
HSPCs transduced in the periphery home back to the BM where they stably express the
transgene. In hCD46 transgenic mice, we showed that our in vivo HSPC transduction
approach allows for the stable transduction of primitive HSPCs. Twenty weeks after in
vivo transduction, green fluorescent protein (GFP)marking inBMHSPCs (Lin2Sca11Kit2
cells) in most of the mice was in the range of 5% to 10%. The percentage of GFP-expressing primitive HSPCs capable of forming
multilineage progenitor colonies (colony-forming units [CFUs]) increased from 4%of all CFUs at week 4 to 16%at week 12, indicating
transduction andexpansionof long-termsurvivingHSPCs.Our approachwaswell tolerated, did not result in significant transduction
of nonhematopoietic tissues, and was not associated with genotoxicty. The ability to stably genetically modify HSPCs without the
need of myeloablative conditioning is relevant for a broader clinical application of gene therapy. (Blood. 2016;128(18):2206-2217)
Introduction
Hematopoietic stem/progenitor cells (HSPCs) are an important gene
therapy target, as recentclinical trialshaveshownclear therapeuticbenefits
for otherwise incurable blood diseases.1 Current HSPC gene therapy
protocols involve the transplantation of ex vivo lentivirus vector trans-
duced HSPCs and are associated with a number of drawbacks. Ex vivo
culturing of HSPCs in the presence of multiple cytokines can affect their
multipotency and engraftment potential. Furthermore, most protocols
involve myeloablation resulting in blood-cell depletion and susceptibility
to infections and mucosal damage. Thus, the development of an in vivo
HSPC transduction approach, circumventing conditioning and trans-
plantation would be highly desirable.
Direct transduction of HSPCs localized in the bone marrow (BM) is
inefficient because of physical barriers formed by the BM stroma.
Mobilization, an enforced egress of HSPCs from the BM, can be
achieved by a variety of approaches.2 A combination of granulocyte
colony-stimulating factor (G-CSF) and the CXCR4 antagonists
AMD3100 (Mozobil, Plerixa) has been shown to efficiently mobilize
primitive progenitor cells in animal models and in humans.3 A problem
for in vivo HSPC transduction is the low number of HSPCs in the
BM. Only about 1 in 108 nucleated marrow cells are HSPCs4; the vast
majority of cells in theBMare blood cell progenitor cells with different
levels of lineage commitment. A long-term therapeutic effect of gene
therapy requires that gene transfer vectors target these rare HSPCs.
CD46 complement regulatory protein is expressed on all human
HSPCs.5 We identified CD46 as the high-affinity receptor for a number
of adenoviruses (Ads), including serotype 11, 16, 21, 35, and 50.6 The
receptor interactingmoiety in the capsidofAds is theC-terminalglobular
trimeric fiber domain, called the fiber knob. Both others and we have
shown that Ad vectors containing the Ad35 fiber or fiber knob (Ad5/35)
efficiently transduce human and non-human primate HSPCs in vitro.7-10
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Materials and methods
Reagents
G-CSF/Filgrastimwas fromAmgen (ThousandOaks,CA).AMD3100was from
Sigma (St. Louis, MO).
Ad vectors
The first-generation Ad5/3511-green fluorescent protein (GFP) vector,11
Ad5-GFP vector,8 and the Sleeping Beauty (SB) 1003 transposase encoding
helper-dependent adenovirus (HD-Ad)-SB vectors12 are described else-
where. Generation of the transposon vector HD-Ad–GFP genome using a
recombineering strategy13 is described in detail in the supplemental Methods
(see “Adenovirus vectors”), available on the BloodWeb site.
Cells
Human CD341-enriched cells from G-CSF mobilized normal donors were
obtained from the Fred Hutchinson Cancer Research Center Cell Processing
Core Facility and cultured as described previously.8 Colony-forming unit (CFU)
assays were performed using ColonyGEL (ReachBio, Seattle, WA) human or
mouse complete medium according to the manufacturer’s specifications.
Tissue immunofluorescence analysis
Before tissue harvest, blood was flushed from the circulation with phosphate
buffered saline using the heart as a pump. Tissues were frozen in optimal cutting
temperaturecompound.Sections (6mm)werefixed in4%paraformaldehydeand
either remained unstained or was stained with rat anti-mouse CD45 primary
antibody (Ab) (BD Biosciences, Franklin Lakes, NJ). Specific binding of
primary Abs was visualized with secondary anti-rat Alexa Fluor 488 Ab. After
washing, the slidesweremountedwithVectashield containing49,6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories, Inc., Burlingame, CA). Immunoflu-
orescence microphotographs were taken at room temperature on a Leica DMLB
microscope (403 oil lens) (Leica, Wetzlar, Germany) with a Leica DFC300FX
digital camera and Leica Application Suite version 2.4.1 R1 (Leica Micro-
systems, Heerbrugg, Switzerland).
Integration site analysis
Genomic DNA was isolated from GFP1 hCD46tg colonies using the DNeasy
Blood andTissueKit (Qiagen,Valencia,CA). TheseCFUcolonieswere obtained
fromLin2/GFP1BMcells of in vivo transducedhCD46tganimals.Amplification
of SB genomic DNA junctions was performed by linear amplification-mediated
polymerase chain reaction (PCR) as described previously14 and in detail in the
supplemental Methods (see “Construction of integration site libraries”).
Mouse studies
hCD46-transgenic mice
C57Bl/6 based transgenic mice that contained the human CD46
genomic locus and provide CD46 expression at a level and in a pattern
similar to humans were described earlier.15
Mobilization and in vivo transduction. HSPCsweremobilized
inmice by subcutaneous (SC) injections of human recombinantG-CSF
(5mg/d per mouse, 4 days), followed by an SC injection of AMD3100
(5 mg/kg) on day 5. In addition, animals received dexamethasone
(10 mg/kg) intraperitoneally (IP) 16 hours and 2 hours before virus
injection. Fortyminutes afterAMD3100, animalswere IV injectedwith
Ad vectors through the retro-orbital plexuswith a total dose of 431010
viral particles (vp). In double injection settings, animals received up to
4 3 1010 vp twice at 30 minutes and 60 minutes after AMD3100
injection.
Secondary BM transplantation. Recipients were female
C57BL/6 mice, 6 to 8 weeks old. On the day of transplantation, re-
cipient mice were irradiated with 1000 Rad. BM cells from in vivo
transduced hCD46tg mice were isolated aseptically and GFP1 cells
were isolated usingfluorescence-activated cell sorting. Four hours after
irradiation, GFP1 cellswere IV injected through the tail vein at 13106
cells per mouse.
Generation of humanized non-obese diabetic/severe combined
immunodeficiency/interleukin (IL)-2Rgnull (NOG) mice. The im-
munodeficient NOGmicewere obtained fromThe Jackson Laboratory
(Bar Harbor, ME). NOG recipient mice received 300 Rad whole body
irradiation; 2.5 3 105 whole BM cells of non-irradiated NOG mice
were mixed with 3 3 105 human CD341 cells and IV injected into
recipient mice at 4 hours post-irradiation.
Results
Transient in vivo transduction of mobilized BM cells with
a first-generation Ad5/3511 vector
Although CD46 is expressed on all nucleated cells in humans, the
corresponding mouse ortholog is only expressed in the testes. For
in vivo HSPC transduction studies, a transgenic mouse model
(hCD46tg) expressing hCD46 in a pattern and at a level similar to
humans was used.15 In hCD46tg mice, hCD46 is expressed at high
levels in BM HSPCs (Figure 1A). This fraction is depleted for
blood lineage cells (Lin2) and positive for c-Kit and Sca-1 (so
called Lin2Sca11Kit1 [LSK] cells).16 hCD46 expression was higher
on LSK than on more differentiated Lin2 and total mononuclear cells
(MNCs). We employed G-CSF/AMD3100 to mobilize HSPCs from
the BM of hCD46tg mice. Mobilization resulted in a ;100-fold
increase of LSK cells in peripheral blood at 40 minutes after
AMD3100 injection as shown by flow cytometry (Figure 1B) and
CFU progenitor assays (Figure 1C).
Initial transduction studies employed an affinity-enhanced first-
generation Ad5/35 vector expressing GFP and carrying a modified
Ad35 fiber knob with a 25-fold increased affinity to hCD46
(Ad5/3511-GFP).11 hCD46-tg mice were mobilized with G-CSF
and AMD3100, and 40 minutes after AMD3100, Ad5/3511-GFP
was IV injected. At 2 hours after transduction, 24% of peripheral
blood LSK cells were GFP1, indicating efficient transduction of
circulating mobilized HSPCs (Figure 1D). Direct transduction of
BM and splenic LSK cells was inefficient with 0.7% and 2.7%
GFP1 cells, respectively. Mobilized, transduced LSK cells left
the periphery by day 3 after transduction (Figure 1E). At the same
time, GFP1 LSK cells could be detected in the BM and spleen
(Figure 1F). In the BM, 7.6% of LSK cells had been transduced,
whereas only 0.3% of total MNCs were GFP1, showing pre-
ferential transduction of HSPCs. In the spleen, 13% of LSK cells
and 1.2% of total MNCs expressed GFP, respectively. Without
mobilization, 0.3% and 3.5% of LSK cells in the BM and spleen,
respectively, were GFP1 at day 3. The percentage of GFP1 LSK
cells in the BM decreased over time with 3.4% and 2.1% positive
cells at days 7 and 14, respectively. A faster decline was observed
in transduced splenic LSK cells. The loss of GFP1 cells over
time could be due to: (1) differentiation of LSK cells; (2) vector
cytotoxicity associated with leaky expression of viral genes from
the first-generation Ad5/3511-GFP genomes17; (3) loss of epi-
somal, non-integrated Ad vector genomes during cell division;
and/or (4) competition by nontransduced HSPCs.
BLOOD, 3 NOVEMBER 2016 x VOLUME 128, NUMBER 18 IN VIVO HEMATOPOIETIC STEM CELL GENE THERAPY 2207
For personal use only.on November 7, 2016. by guest  www.bloodjournal.orgFrom 
Sc
a-
1
c-kit
non-mobilized mobilized
BA
hCD46
iso LSK
MNCs
Co
un
t
hC
D4
6 
M
FI
0
5000
10000
15000
*
*
LS
Klin
-
MN
Cs
C
CF
U/
10
0 
µL
 b
lo
od
0
500
1000
1500
2000
G-CSF
AMD3100
time post AMD3100
- + ++
- - + +
3 h40 min
****
****
****
+
+
3 d
+
+
14 d
+
+
7 d
E
Time posttransduction
%
GF
P+
 L
SK
 c
el
ls
2 h 6 h 3 days mock
0
10
20
30
*
**
***
D
0
10
20
30
%
 G
FP
+  
LS
K 
ce
lls
***
***
PB
MC BM
Sp
lee
n
F
total MNCs
2 3 7 14 2 3 7 14 2 3 7 14 2 3 7 14
0.01
0.1
1
10
100
dpi
BM Spleen
LSK
n.s. * n.s. *
Mobil. - ++ + - ++ + - ++ + - ++ +
%
 G
FP
+
Figure 1. In vivo transduction of mobilized HSPCs with a first-generation Ad5/3511 vector after mobilization. (A) hCD46 expression on BM total MNCs, lineage-
depleted BM cells (Lin2), and LSK cells from hCD46tg mice. Representative hCD46 flow cytometry analysis with MNC (solid black) and LSK cells (dashed black) (left). The
gray curve represents MNCs stained with an isotype-matched control. hCD46 MFI on MNCs, Lin2, and LSK cells (right). N 5 3. *P , .05, after one-way analysis of variance
(ANOVA) with Tukey’s multiple comparison test. (B) Mobilization of LSK cells in hCD46tg mice by SC G-CSF injection for 4 days, followed by a single SC injection of
AMD3100 on day 5. Forty minutes after the AMD3100 injection, PBMCs were harvested and analyzed by flow cytometry for LSK cells. Representative plots of nonmobilized
and mobilized mice are shown. (C) Analysis of HSPC mobilization based on CFU formation. PBMCs were collected before onset of mobilization treatment, before injection of
AMD3100, 40 minutes and 3 hours after the AMD3100 injection, as well as on days 3, 7, and 14 after mobilization. The collected cells were subjected to CFU assays and
colonies were enumerated 12 days after plating. Shown are mean 6 standard deviation (SD), colonies normalized to a blood volume of 100 mL. N 5 3. (D) A total of 4 3 1010
vp of the first-generation Ad5/3511-GFP vector was IV injected 40 minutes after AMD3100. To alleviate release of pro-inflammatory cytokines associated with IV Ad vector
injection, animals received dexamethasone (10 mg/kg) IP 16 hours and 2 hours before virus injection. Early transduction was analyzed by harvesting PBMCs, BM, and spleen
cells at 2 hours after virus injection, and culturing them for 48 hours to allow for GFP expression. Shown is the percentage of GFP1 cells in the LSK cell fractions (analyzed by
flow cytometry). N 5 3. (E) Animals were mobilized and injected with Ad5/3511-GFP as before. Animals were euthanized and PBMCs collected at 2 hours and 6 hours after
transduction. The cells were cultured for 48 hours to allow for GFP expression. Shown is the percentage of GFP1 LSK cells. In addition, GFP expression in peripheral blood
LSK cells was analyzed at 3 days after transduction, without culturing of the cells. Unmobilized, untransduced animals were used as controls (mock). N 5 3. (F) Animals were
mobilized and injected with Ad5/3511-GFP as before. Transduction was analyzed by harvesting BM and splenic cells at day 3, 7, and 14 after Ad5/3511-GFP injection.
Nonmobilized control animals were euthanized 2 days after infection. Shown is the percentage of GFP1 cells within total MNCs, and LSK cells in the BM and spleen. N 5 3.
Values represent means6 SD. *P, .05; **P, .01; ***P, .001; ****P, .0001, after unpaired Student t test comparing nonmobilized controls with animals euthanized 3 days
after transduction. dpi, days postinfusion; Iso, isolated; MFI, mean fluorescence intensity; Mobil, mobilized; n.s., not significant.
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Stable in vivo transduction of HSPCs with integrating
HD-Ad5/3511 vectors
To address the problem of first-generation vector-related cytotoxicity
and to allow for chromosomal integration of the transgene, we used
a hyperactive SB transposase (SB1003) system in the context of
HD-Ad5/3511 vectors that lack all viral genes. The system consists of
2 vectors (Figure 2A). The transposon vector HD-Ad–GFP contains a
GFP gene under the control of the EF1a promoter, a promoter that is
active in HSPCs. The transgene cassette is flanked by inverted repeats,
which are recognized by SB1003 and frt sites for circularization of
the transgene cassette through Flpe recombinase. The second vector,
HD-Ad–SB, supplies Flpe and SB1003 in trans to mediate integration
of the GFP cassette into a thymine-adenine dinucleotide of the geno-
mic DNA.18 Both vectors contain the affinity-enhanced Ad3511 fiber
knob. In vitro studieswith hCD46tgLin2 cells (supplemental Figure 1)
and MO7e cells, a model cell line for human HSPCs (supplemental
Figure 2), demonstrated efficient transgene integration through the
SB1003 vector system.
The two-vector system was then used for in vivo HSPC transduc-
tion in hCD46tg mice. First, we determined that doubling the vector
dose (2 injections of each 4 3 1010 vp given 30 and 60 minutes
after AMD3100) significantly increased the percentage of transduced
LSK cells in peripheral blood (P, .05; supplemental Figure 3). This
treatment regimen was used for all subsequent studies. For in vivo
studies, mobilized animals received a combination of HD-Ad–SB and
HD-Ad–GFP (Figure 2B). At 3 days after in vivo transduction, GFP
expression in CD31, CD191, and Gr-11 hematopoietic lineages and
HSPCs was analyzed in the BM, spleen, and peripheral blood mono-
nuclear cells (PBMCs) (Figure 2C). This analysis showed that: (1) our
vectors not only transduce mobilized LSK cells but also differentiated
cells; (2) mobilization significantly increased GFP marking of LSK
cells in the BM and spleen; and (3) not only transduced mobilized
LSK cells but alsoCD191 cells appeared to return back to theBMafter
transduction in the periphery.
To evaluate stable long-term transgene expression after HSPC
transduction, groups of mice were injected with both vectors, or HD-
Ad–GFPalone and euthanized 4, 8, 12, and 20weeks after transduction
(Figure 2D). Total BM MNCs of animals injected with both vectors
showedGFP in 2.5%, 1.1%, 0.4%, and 0.9% of cells at 4, 8, 12, and 20
weeks after transduction. The loss of transduced cells over time was
most likely due to exit or turnover of short-term reconstituting HSPCs
and differentiated cells.19 Animals that received HD-Ad–GFP alone
showed a significantly lower transduction with 0.4% at 4 weeks after
transduction (P, .001) and transduction levels remained low at later
time points. Overall, higher transduction rates were observed for BM
LSK cells, again suggesting preferential transduction ofmore primitive
cells. Up to 7.7% (average 5 2.45%) of all BM cells were GFP1 at
week 4 after injection. The percentage ofGFP1 cells declined over time
during week 8 and 12, and increased again at week 20 to 5% to 10% of
GFP1 LSK cells in most animals.
In the spleen of animals injected with both vectors, GFP was
expressed in 11.8%, 17.6%, 5.7%, and 16.1%of cells at 4, 8, 12, and 20
weeks posttransduction, suggesting transient expansion of transduced
cells or influx of modified, BM-derived cells.
In the blood, rapid loss of transgene expression could be observed
in most animals, most likely due to anti-GFP immune responses,
eliminating GFP-marked PBMCs, as supported by the occurrence
of high serum titers of anti-GFP Abs and GFP-specific CD8 T cells in
the spleen of mice that were euthanized at week 20 after in vivo
transduction (supplemental Figure 4). Notably, stable transduction of
splenocytes with the HD-Ad–GFP vector alone was also observed in
some animals. Although this observation is consistent with a low
frequency of integration of HD-Ad vectors through their inverted
terminal repeats reported earlier,20 it requires further investigation.
Differentiation of transduced HSPCs into lineage-positive cells is
supported by the analysis ofGFP expression inCD3,CD19, andGr-11
cells present in the BM and spleen at day 3, week 8, and week 20 after
transduction (Figure 2E). GFP marking of CD3 and CD19 cells in the
BMwas higher at week 8 than at day 3. In the spleen, increases in GFP
marking over timewere seen forCD191 andGr-11 cells, suggesting an
influx of modified cells derived from HSPCs in the BM, rather than
initial transduction or expansion of the cells in the spleen. The fact that
the CD191 cells turnover is less than 4 weeks21,22 and that modified
cells are detected at much later time points, support this hypothesis.
Notably, changes in the levels of BM CD191 and Gr-11 cells were
observed after in vivo transduction, independent of animals’ mobili-
zation status. In the spleen and blood however, a clear influence of
the mobilization on the lineage composition was observed (supple-
mental Figure 5).
To support theseflowcytometric analyses, a functionalHSPCassay
were performed. First, the ability of GFP1 lineage-depleted BM cells
harvested at week 4, 8, 12, and 20 after HD-Ad injection to form
multilineage progenitor colonies (or CFUs) was analyzed (Figure 3A).
The percentage of GFP1 CFUs increased during the first 12 weeks in
treated animals, suggesting enrichment of transduced colony-forming
cells and the loss of transduced less primitive cells (Figure 3B). At
12weeks after transduction, 16.5%of colony-forming cellswere stably
modified. At week 20, markedly fewer colonies were formed with
lower rates of genemodification,most likely due to the animals’old age
(;8 months), which is associated with HSPC deterioration.23 Of 80
GFP-positive colonies screened, 30.9%were granulocyte, erythrocyte,
monocyte, megakaryocyte CFU, 29.4%were granulocyte/macrophage
progenitors CFU, 14.7%were granulocyte CFU, 13.2%were erythroid
burst-forming unit, and 11.7% were erythroid CFU, suggesting that
multipotent progenitorswere efficiently transduced (Figure 3Canddata
not shown).
Additionally, BM of in vivo transduced hCD46tg animals was
used to rescue lethally irradiated C57BL/6 recipients to assess the
multilineage, long-term reconstitution potential of gene-modified
HSPCs (Figure 4A). Successful engraftment, based on hCD46
expression in PBMCs, was achieved in 6 out of 7 animals (Figure 4B).
GFP marking rates in PBMCs were on average 9% and remained
stable (Figure 4C). At week 16, animals were euthanized and GFP
markingwas assessed in cells of the BM, spleen, lungs, and thymus,
as well as in PBMCs. Analysis of BM showedGFP1HSPCs (Lin2,
LSK, and LSK SLAM) (Figure 4D). In the BM, GFP marking was
seen in 5.9% of Lin2 cells, in 8.6% of LSK cells, and in 4.6% of
primitive LSKSLAM(LSK,CD1501, CD482) cells. GFPmarking
was also detected in CD3, CD19, CD11b, and Gr-11 cells of the
BM, spleen, and blood (Figure 4E), as well as in leukocytes in the
lung and thymus (Figure 4F). Furthermore, GFP marking was
detected in microglia in the brain as well as in leukocytes found in
the lumen of intestinal villi of the small intestine, both most likely
derived from transduced HSPCs (supplemental Figure 6). We
cannot explain why after transplantation of GFP-positive HSPCs,
engraftment rates were over 90%, but GFP-positive cells were only
about 9%. We hypothesize that this is due to either the presence of
GFP1 cells without stable vector integration in the transplant or the
development of anti-GFP immune responses in transplant recipi-
ents, leading to the killing of GFP-expressing PBMCs.
Taken together, the CFU and in vivo repopulation data suggest
that our HD-Ad–SB 1 HD-Ad–GFP vector system can transduce
and stably modify long-term reconstituting hematopoietic stem cells
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(HSCs), which then give rise to transgene-expressing progeny. More-
over, no abnormalities in blood cell counts/blood chemistry and tissue
histologywere found in transplant recipients, suggesting the absence of
oncogenic or inflammatory events (supplemental Figure 7).
Safety of IV HD-Ad5/3511 vector injection
Although the IV injection of first-generation Ad5/35 vectors was
shown to be safe in hCD46tg mice24 and baboons,25 the safety of
IV injections of HD-Ad5/3511 vectors into mobilized animals had to
be shown. The bio-distribution of HD-Ad–GFP was assessed by
quantitative PCR and on tissue sections at 3 days after injection into
mobilized animals. Vector genomes were detected in the lung, liver,
heart, kidney, and spleen at levels between 5 and 20 genome copies per
cell (Figure 5A).26-28 Vector DNA levels in the gastrointestinal tract and
ovaries were 2 orders of magnitude lower. We speculate that the vector
PCR signals in the lung, liver, kidney, and spleen reflect transduced
leukocytes either as part of residual blood or as tissue infiltrates. This is
supported by immunofluorescence studies on liver sections showingGFP
expression in CD451 leukocytes (Figure 5B, middle panel). To illustrate
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Figure 3. In vivo transduction of HSPCs with CFU
potential. hCD46tg animals were mobilized and in vivo
transduced with HD-Ad–GFP (n5 6 for 4 and 8 weeks,
and n5 5 for 12 weeks after transduction) alone or with
a combination of HD-Ad–GFP and HD-Ad–SB (n 5 5
for 3 days, n 5 10 for 4 weeks, n 5 12 for 8 and
12 weeks, and n 5 5 for 20 weeks post-transduction).
Animals were euthanized 3 days, 4, 8, 12, or 20 weeks
after transduction, BM cells were isolated, lineage
depleted via MACS, and followed by the collection of
GFP1 cells via fluorescence-activated cell sorting.
Cells were then plated in CFU assays and colonies
were scored 12 days after plating. (A) Experimental
design. (B) Total colonies formed per 1000 plated Lin2
cells (left) and percentage of GFP1 colonies among
total CFUs (right). Shown are single animals as well
as group means. (Open circles, HD-Ad-GFP; filled
squares, HD-Ad-SB 1 HD-Ad-GFP.) Two-way ANOVA
with Bonferroni posttesting for multiple comparisons 5
n.s. ***P , .001. (C) GFP expression in progenitor
colonies. Examples for GFP1 erythroid burst-forming
units, CFUs of erythroid progenitors (erythroid CFU),
granulocyte progenitors, granulocyte/macrophage
progenitors, and multipotential progenitor cells (granulo-
cyte, erythrocyte, monocyte, and megakaryocyte CFUs)
are shown. The scale bar is 500 mm. No specific
feature within images shown in panel C was enhanced,
obscured, moved, removed, or introduced. BFU-E,
erythroid burst-forming unit; CFU-E, erythroid CFU;
CFU-G, granulocyte CFU; CFU-GEMM, granulocyte,
erythrocyte, monocyte, and megakaryocyte CFU;
CFU-GM, granulocyte/macrophage CFU; MACS, magnetic-
activated cell sorting; n.s., not significant.
Figure 2 (continued) different lineages as well as LSK cells and total MNCs were analyzed via flow cytometry. N 5 5. *P , .05 after two-way ANOVA with Bonferroni
posttesting.**P , .01; ***P , .001; ****P , .0001. (D) GFP expression in total BM (upper left), spleen (lower left), and peripheral blood MNCs (lower right), as well as BM LSK
cells (upper right). Circles represent animals injected with HD-Ad–GFP only (N5 6). Squares represent animals injected with HD-Ad–GFP1 HD-Ad–SB euthanized at 3 days
(N 5 5), 4 (N 5 10), 8 (N 5 10), 12 (N 5 11), and 20 weeks (N 5 5) after transduction. Each data point represents a single animal. **P , .01. (E) GFP marking in
hematopoietic lineages of BM and spleen. Animals were euthanized 3 days as well as 8 and 20 weeks after transduction, and GFP expression in different lineages was
analyzed via flow cytometry. Shown is the mean6 SD percentage of GFP1 cells in the indicated lineages. ****P, .0001. Some of the data, eg, the decrease in GFP1/CD191
cells and the increase in GFP1/Gr-11 cells in the BM between weeks 8 and 20 cannot be readily explained. ITR, inverted terminal repeats; PGK, phosphoglycerate kinase.
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the absence of hepatocyte transduction by HD-Ad–GFP, we injected
mobilizedmice with a GFP-expressing Ad serotype 5 (Ad5-GFP). Three
days later, the Ad5-GFP injection yielded ;50% of GFP1 hepatocytes
(Figure 5B, lower panel), whereas no hepatocyte transduction was
observed with HD-Ad–GFP. In line with this, HD-Ad–GFP caused no
liver toxicity (as reflected in alanine aminotransferase and aspartate
aminotransferase levels) in contrast to theAd5 vector (Figure 5C). Serum
levels of cytokines IL-6, IL-10, tumor necrosis factor-a, IL-12p70, and
interferon-g were below the detection limit of the cytometric bead
array used for detection (Figure 5D). Levels of the pro-inflammatory
chemokine membrane cofactor protein-1 were elevated compared
with untreated animals but still markedly lower than in other studies
with Ad vectors,29 most likely due to dexamethasone administration
before virus injection.30
The genotoxicpotential of SB1003-mediated transgene integration
after in vivo transduction was assessed in genomic DNA isolated from
GFP1 progenitor colonies through genome-wide integration analysis
using linear amplification method-PCR and next-generation sequenc-
ing. A total of 155 distinct SB1003-mediated integration sites were
identified (Figures 6A-B). Integration into intergenic and intronic
regions had occurred in 64% and 34% of events, respectively, whereas
1.3%of integrationswere in exons (Figure 6C).No integrationwithin or
near a proto-oncogene was found (supplemental Figure 8A). The
average distance to the closest cancer-related gene was 1689 kb. The
level of randomness of integration was 72% without preferential
integration in any given window of the whole mouse genome
(supplemental Figure 8B).Wehave analyzed inmoredetail the potential
integration “hotspot” on chromosome 13. None of the integrations in
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Figure 4. Gene-modified HSPCs are capable of long-term, multilineage reconstitution of lethally irradiated recipients. (A) Experimental design. BM harvested from
hCD46tg mice 8 weeks after in vivo transduction with HD-Ad–GFP and HD-Ad–SB was sorted for GFP1 cells. A total of 13 106 GFP1 cells per recipient (pooled from different
mice) were transplanted into lethally irradiated C57BL/6 mice. PBMCs were collected 4, 6, 8, 10, 12, and 14 weeks after transplantation, and analyzed for hCD46 and GFP
expression by flow cytometry. N 5 7. (B) Engraftment rate of transplanted cells based on hCD46 flow cytometry of PBMCs. Shown are single animals (filled squares) and the
mean. (C) Percentage of GFP1 PBMCs analyzed at the indicated time points. (D) Week 16 GFP marking in BM lineage-depleted cells and cell fractions enriched for HSPCs
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this region occurred within genes and near genes associatedwith cancer
development.
In vivo HSPC transduction in humanized mice
The hCD46 levels in human CD341 cells were slightly increased
in the more primitive CD341/CD382 subfraction (Figure 7A),
However, in human PBMCs spiked with CD341 cells, no differ-
ences in CD46 levels between CD341 and CD342 cells were found
(supplemental Figure 9). We first demonstrated, in vitro, in pro-
genitor colony assays that the co-infection of human CD341 cells
with HD-Ad–SB and HD-Ad–GFP resulted in stable transduction,
indicating that our vector system is functional in human HSPCs
(supplemental Figure 10).
To establish humanized mice, we transplanted human CD341 cells
into sublethally irradiated, immunodeficient NOG mice. Average
engraftment rates at 6 weeks after transplantation were 25% based on
huCD451 cells in the blood. Of note, all human cells express the
HD-Ad5/3511 receptor hCD46. G-CSF/AMD3100 mobilization led
a 2.3- and 8.2-fold increase in circulating human and murine CFU,
respectively, showing inferior mobilization performance compared with
our hCD46tg mouse model (Figure 7B). This is most likely due to
abnormal BM structure and hematopoiesis observed in NOG mice.31
Three days after mobilization andHD-Ad–GFP1HD-Ad–SB injection,
GFP expression was analyzed in the BM, spleen, and PBMCs in
huCD451 cells and in more primitive subfractions (CD341 and c-Kit1)
(Figure 7C). In the BM,;0.5% of huCD451 cells were GFP1, whereas
the GFP marking rate in the CD341 cell fraction was approximately
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twofold higher. This was even more pronounced in the spleen, where
43.6- and 22.3-fold more GFP1/CD341 and GFP1/c-Kit1 cells than
GFP1/CD451 cells were found, respectively. To assess stable trans-
duction and expansion of transduced cells, GFP expression in
huCD451 cells was compared at day 3 and week 4 after in vivo trans-
duction (Figure 7D). In the BM, 0.2% and 2.5% of huCD451 cells
were GFP1, 3 days and 4 weeks after transduction, whereas in the
spleen GFPmarking was 0.1% and 7.6%, respectively, showing expan-
sion of transduced human HSPCs.
Mobilization resulted ina drastic increase inCD31cells particularly
in the BM, and to a lesser degree in the spleen and blood (Figure 7E).
This can in part be explained by the fact that the lymphoid compartment
in NOG mice is mostly depleted, which provides space for expansion
of existing lymphoid cells. Notably, GFP marking in CD31 cells was
very low (0.075%) at 3 days after transduction and decreased further
by 4 weeks after transduction, possibly due to the strong expansion of
CD31 cells (Figure 7F). Importantly, GFPmarking inmyeloid CD331
cells in the BM greatly increased (13-fold) between day 3 and week 4.
Although at 3 days after transduction no GFP1/CD191 cells were
detected, 1.2% of CD191 cells were GFP1 4 weeks after transduction,
strongly suggesting that HSPCs as well as myeloid and lymphoid
progenitors had been transduced and differentiated, and expanded over
time. Further studies over a longer time period are required to support
this conclusion.
Discussion
Here, we demonstrate that we can stably genetically modify rare,
primitive, long-term reconstituting HSPCs, a prerequisite for a long-
term/life-long genetic cure of inherited and acquired diseases.4Atweek
20, we detected GFP marking in 6.4% of BM LSK cells (Figure 2D),
which corresponds to ;0.05% of all total mononuclear BM cells.
We did not find published data on lentivirus vector-mediated, long-
term gene marking in BM HSCs in mice. In non-human primate and
human studies with ex vivo lentivirus vector-transduced HSCs, it was
estimated that one in 1 million transplanted HSCs were capable of
long-term repopulation.32,33 In the human trials, this would correspond
to 200 to 300 gene-corrected, long-term engrafting cells per 1.53 1012
total MNCs in the human BM.4 The fact that our approach allows for
the transduction of primitive HSPCs and that the percentage of these
cells increases over time (Figure 3B), suggests that transduced HSPCs
self-renew and give rise to GFP1 progeny cells that slowly overtake
the BM.
Our new technology for in vivo HSPC transduction is based on a
number of novel features, as shown in the sections to follow.
Mobilized HSPCs can be transduced with HD-Ad5/3511 vectors
in the periphery, and home back to the BM and spleen
HSPCs in the BM cannot be efficiently transduced by IV injected
gene transfer vectors, even if they express the targeted receptor.
Limited accessibility of HSPCs and/or hCD46 due to BM stroma
and inefficient virus extravasation from blood vessels could
account for this. The rigidness of BM stroma and limited space in
the BM also makes direct intra-osseous injection of gene transfer
vectors or cells inefficient and difficult to control.34,35 Here, we
show that G-SCF/AMD3100 mobilization can circumvent these
problems and allow for the transduction of mobilized HSPCs
(Figures 1F and 2C). Within 2 hours after IV vector injection,
;25% of mobilized LSK cells were transduced. By day 3 after
injection, no GFP1 LSK cells remained in the peripheral blood;
concurrently GFP-expressing LSK cells appeared in the BM and
spleen.
HD-Ad5/3511 vectors efficiently transduce primitive HSPCs
In the BM of both the hCD46tg and NOG/hCD341 mice,
transduction levels at day 3 were higher in HSPCs compared with
total MNCs (Figures 1F, 2C, and 7C). In hCD46tg mice, this can be
attributed to higher hCD46 levels onHSPCs (Figure 1A). Targeting
of long-term surviving, multipotent HSPCs by HD-Ad5/3511
vectors is supported by CFU and in vivo repopulation assays
(Figures 3C and 4). Compared with lentivirus and recombinant
adeno-associated virus vectors, additional advantages of HD-Ad5/
3511 vectors inHSPC gene therapy include: (1) the large transgene
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Figure 6. Analysis of vector integration sites in
HSPCs. Genomic DNA isolated from 20 pooled GFP1
progenitor colonies from BM cells of female hCD46tg
animals, harvested 8 weeks after HD-Ad–GFP 1 HD-
Ad–SB in vivo transduction and SB-mediated transgene
integration sites were recovered. (A) Chromosomal
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insert capacity (30 kb); (2) no requirement for cell cycling7; and (3)
the relatively low manufacturing costs.
HD-Ad5/3511 vectors encoding SB transposase allow for
transgene integration in HSPCs
A major advantage of the SB1003 integration system is its in-
dependence of the cellular DNA repair and recombination machinery,
the low activity ofwhich inHSPCs (which are, per se, quiescent), limits
other integration strategies involving nonhomologous end joining
or homologous recombination.36 In contrast to lentiviral37 or adeno-
associated virus vectors,38 SB1003-mediated integration is not biased
toward insertion into or near genes,12 leading to a lower risk of
genotoxic events. GFP marking rates with the HD-Ad5/3511-based
SB1003 system varied between individual animals. We excluded
that these differences were due to inefficient HSPCmobilization in a
subset of mice. The numbers of CFU in the blood 2 hours after
AMD3100 were comparable between individual mice (data not
shown). Furthermore, GFP marking analyzed at day 3 did not show
dramatic differences between animals. A potential explanation for
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Figure 7. HSPC in vivo transduction in a humanized mouse model. (A) CD46 MFI on human CD341 and CD341/CD382 cells derived from umbilical cord blood MNCs.
(B-D) In vivo studies in humanized mice. NOG mice received whole body irradiation and were transplanted with human CD341 cells. Six weeks after transplantation,
successful engraftment was confirmed by huCD45 flow cytometry of PBMCs. Animals were then mobilized and injected with HD-Ad–SB 1 HD-Ad–GFP. (B) Mobilization of
human HSPCs. PBMCs were collected 90 minutes after AMD3100. PBMCs were plated in CFU assays in the presence of human or murine cytokines. Total CFU were
enumerated 12 days after plating. N 5 2. Differences between mobilized and nonmobilized animals were not statistically significant after unpaired Student t tests. (C) GFP
expression in total human CD451 cells and in HSPCs (CD341 or c-Kit1 cells) in the BM, spleen, and PBMCs 3 days after HD-Ad–SB 1 HD-Ad–GFP injection into mobilized
mice. N 5 2. **P , .01 after one-way ANOVA with Bonferroni posttesting. (D) GFP expression in human (hCD451) cells in the BM and spleen at day 3 (N 5 4) and week 4
(N5 7) after in vivo transduction with HD-Ad–SB1 HD-Ad–GFP. Values represent mean6 SD. ***P, .001 after one-way ANOVA with Bonferroni posttesting. (E-F) Lineage
composition of hematopoietic tissues and transgene expression in hematopoietic lineages following HSPC in vivo transduction. Humanized NOG mice were mobilized and
injected with HD-Ad–SB 1 HD-Ad–GFP as before. Animals were euthanized at 3 days (n 5 2) or 4 weeks (n 5 3) after transduction, and expression of GFP and lineage
surface markers was assessed via flow cytometry. (E) Expression of hematopoietic lineage surface markers after HSPC in vivo transduction in the BM, spleen, and peripheral
blood. An unmobilized, untreated, humanized NOG animal was used as control (mock). Shown are mean 6 SD. (F) GFP expression in hematopoietic lineages at 3 days and
4 weeks after HSPC in vivo transduction. Shown are mean 6 SD. *P , .05 following two-way ANOVA with Bonferroni posttesting. **P , .01; ***P , .001. iso, isolated; n.s.,
not significant; mobil, mobilized.
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the variations in GFPmarking in individual animals at week 8 and 20
could be related to the fact that true HSPCs are rare, and might not
have been transduced in all animals. Also, the impact of anti-GFP
immune responses on GFP marking in the BM could be considered.
IV injection of HD-Ad5/3511 vectors into mobilized hCD46tg
mice was safe
Our studies in mobilized hCD46tg mice demonstrate that IV injection
of HD-Ad5/3511 vectors was well tolerated. Ongoing studies in non-
human primates corroborate this conclusion.
Innate acute toxicity is a major problem of systemic administration
of Ad5-based vectors in animals and humans.39-41 Previous studies
showed that release and expression of pro-inflammatory cytokines
associated with vector uptake by the reticulo-endothelial system of the
liver and spleen were markedly lower after IV injection of Ad5/35
vectors than afterAd5vectors.24,25,42-44Furthermore, in contrast toAd5
vectors, our HD-Ad5/3511 vectors do not transduce hepatocytes after
IV injection (Figure 5B), which is in agreement with previous Ad5/35
vector studies in hCD46tg mice and non-human primates.24,25,45,46
HD-Ad5/3511 vectors not only transduced mobilized HSPCs but also
other differentiated peripheral blood and mobilized cells after
IV injection (Figure 2C). However, because of the limited lifespan
of differentiated blood cells, their genetic modification will not criti-
cally affect the safety of our approach. At day 3 after injection, vector
genomes detected in tissues were mostly associated with transduced
blood cells. Importantly, noGFP1cellswere found in germ line tissues,
suggesting that lowhCD46 levels and/or lack of accessibility of hCD46
to IV injected virus vector on nonhematopoietic tissues prevented their
efficient transduction. A problem we encountered in our study was the
development of anti-GFP immune responses that most likely resulted
in the elimination ofGFP-expressing PBMCs. Earlier studies involving
the transplantation of retrovirus-transduced HSPCs also associated
the loss of GFP marking in the periphery with anti-GFP T-cell
responses.47-50 This problem can be addressed by immuno-modulation51
or -suppression47 approaches.
Our data provide a basis for future studies in animal diseasemodels,
aimed at assessing the therapeutic potential of our approach. The
simplicity and cost-effectiveness of the technology is relevant for gene
therapy of inherited or infectious diseases, and cancer.52,53
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Fig.S1. Assessment of SB vector system functionality in hCD46tg mouse lin- cells in vitro. Cells were infected with HDAd-GFP 
alone (2000 vp/cells) or HDAd-SB + HDAd-GFP at the indicated ratios (based on an MOI of 2000 vp/cell of HDAd-GFP) and subjected 
to CFU assays. A) The study shows that a 1:1 ratio of HDAd-SB and HDAd-GFP resulted in more efficient stable transduction of lin- 
cells than a 1:3 ratio, a ratio that had been found to be optimal for hepatocyte transduction with HDAd vectors based on serotype 5.
B) Lin- cells were infected with HDAd-GFP alone (MOI 2000) or HDAd-GFP (MOI 1000) plus HDAd-SB (MOI 1000) and the percent-
age of GFP+ cells in all cells from progenitor colonies harvested at day 12 after plating was analyzed via flow cytometry. 
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Fig.S2. Transgene integration after transduction of MO7e cells with HDAd-SB + HDAd-GFP. A-B) GFP expression in MO7e 
clones. MO7e cells were infected either with HDAd-GFP alone or with a 1:1 mixture of HDAd-SB and HDAd-GFP. Cells were cultured 
for 48 h to allow for transgene expression. GFP+ cells were sorted into 96-well plates using FACS at 1 cell per well. The single clones 
were expanded for 2 weeks and the percentage of GFP+ cells per colony was assessed visually using a UV microscope. A) Shown is 
the distribution of GFP expression for all GFP-positive colonies. Upon expansion of single transduced cells to about 106 cells, more 
than 40% of MO7e clones were found to be stably transduced with HDAd-SB plus HDAd-GFP, whereas stable transduction was less 
than 2% in cells infected with HDAd-GFP alone. B) Colonies exhibiting the highest expression levels of GFP (>30%) were further 
expanded. After expansion the level of GFP expression was analyzed via flow cytometry. Shown are the percentages of GFP-positive 
cells for single colonies as well as the mean. An unpaired T-test was performed to test for statistical significance. C-D) Clones with the 
highest expression levels of GFP were selected and further expanded for integration analysis by Southern Blot. C) SacI restriction 
sites in the HDAd-GFP vector genome are indicated. SacI digestion of non-integrated vector DNA would result in a 2500 bp restriction 
fragment. Sleeping Beauty-mediated integration of the GFP transposon results in SacI fragments of different lengths. D) Southern blot 
analysis of SacI-digested genomic DNA from MO7e clones transduced with HDAd-SB + HDAd-GFP using a GFP-specific probe. Each 
lane represents an individual clone. Fragments of various lengths, indicating integration into different genomic sites, are marked.
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Fig.S3. Effect of increased HDAd-GFP dose on in vivo HSPC transduction. 2x1010 vp of HDAd-GFP was injected once at 40 
min after AMD3100 (1xAd) or twice at 30 and 60 min after AMD3100 (2xAd). Shown is the percentage of GFP+ LSK cells in 
PBMCs harvested two hours after Ad injection. * p<0.05
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Fig.S4. Anti-GFP immune responses. A) Serum anti-GFP antibodies. IgG antibodies against recombinant GFP 
were analyzed in serum of non-transduced mice and serum from mice 3 days and 18 weeks after in vivo HSC 
transduction with HDAd5/35++ vectors.  B)  CD8 T-cell  responses in splenocytes harvested from mice 20 
weeks after in vivo HSC transduction. For in vitro stimulation, splenocytes from naïve hCD46 transgenic mice 
(C57Bl/6 background) were transduced with HDAd-GFP (AdGFP) or an HD-Ad control (AdCo) virus (without 
GFP) at an MOI of 1000 vp/cell, or mock-transdcued, and cultured for three days. For the T-cell assay, cells 
were irradiated at 2500 Rad. Splenocytes from in vivo transduced mice ( N=4) and one naïve mouse were 
harvested 20 weeks after transduction. CD8 cells were isolated using the Miltenyi MACS isolation kit. These 
cells were mixed with stimulator cells at a ratio of 5:1 and incubated for 5 days in the presence of 10U/ml IL-
2. To measure GFP-specific T-cell activation (IFNγ production), C57Bl/6 derived TC1 cancer cells were 
transduced with HDAd-GFP or HDAd-Co and incubated for 3 days (designated “TC1-AdCo” and “TC1-AdGFP” 
target cells in the figure). Target cells were incubated with in vitro stimulated CD8 cells at a ratio of  1:1 and 
IFNγ levels in the supernatants were measured by ELISA (eBioscience) 24 hours later. The red line in the 
figure are T-cell responses from naïve mice that were not in vivo transduced and most likely represent 
background responses to neo-antigens on TC1 tumor cells. The only significant (p<0.05) elevation in IFNγ 
levels over these background levels was seen in the setting with AdGFP stimulated cells on GFP-expressing 
TC1 target cells, indicating CD8 T-cell responses against GFP.    
Bone marrow
%
m
ar
ke
r+
ce
lls
CD
3
CD
19
Gr
-1
0
50
100
n.s. **
***
**
***
PBMC
%
m
ar
ke
r+
ce
lls
CD
3
CD
19
Gr
-1
0
50
100
n.s.
n.s.
****
n.s.
****
Spleen
%
m
ar
ke
r+
ce
lls
CD
3
CD
19
Gr
-1
0
50
100
n.s.
**
*
n.s.
****
n.s.
n.s.
****
***
mobilized - 8w
mobilized - 3d
non-mobilized - 3d
mock
Figure S5. Effect of mobilization and HDAd5/35++ transduction on hematopoietic lineage composition of bone marrow, 
spleen, and peripheral blood. hCD46tg animals were mobilized and transduced with HDAd-GFP + HDAd-SB as before. Animals 
were sacrificed at 3 days and 8 weeks after transduction and the expression of lineage surface antigens in the bone marrow, spleen 
and PBMCs was analyzed via flow cytometry. As controls, unmobilized, uninjected animals (mock), as well as non-mobilized animals 
transduced with HDAd-GFP + HDAd-SB, sacrificed at day 3 after transduction, were used. Shown are mean ±  SD. n.s. not statisti-
cally significant after two-way ANOVA with Bonferroni post testing, comparing treated animals to mock control. * p<0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001.
Brain Intestine
Fig.S6. Immunofluorescence analysis on sections of brain and small intestine from transplanted animals 16 weeks after 
transplantation. The experimental conditions are described in Fig.4. The upper panel shows the merged GFP (green) and DAPI 
(blue) channels. GFP+ cells are indicated by arrows. The lower panels show GFP only. The scale bar is 50 μm.  
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Fig.S7. Blood cell counts of transplanted animals 16 weeks after transplantation. Shown are the counts/µl for white blood cells 
(WBC), neutrophils (NE), lymphocytes (LY), monocytes (MO), eosinophiles (EO), basophiles (BA), red blood cells (RBC) and 
platelets (PLT). Shown are means ± SD. Grey boxes indicated normal ranges. N=7.
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Fig. S8. Analysis of vector integration sites in HSPCs. A) Log-scaled distance (in kb) of each integration site from closest 
genes of KEGG pathways in cancer. The distance is shown in a color gradient, with blue being the smallest distance. B) Integra-
tion pattern in mouse genomic windows. The number of integrations overlapping with continuous genomic windows and random-
ized mouse genomic windows and size was compared. This shows that the pattern of integration is similar in continuous and 
random windows. Maximum number of integrations in any given window was not more than 3; with one integration per window 
having the higher incidence.
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Fig.S9. CD46 expression on human hematopoietic cells. Human PBMCs were spiked with humam CD34+ cells and CD46 expres-
sion was assessed in CD34-positive (red) and CD34-negative (blue) cells via flow cytometry. An isotype-matched control (orange) was 
used to ensure specificity of the stain.
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Fig. S10. Analysis of SB100x-mediated transduction of human CD34+ cells. CD34+ were infected with HDAd-GFP or 
HDAd-GFP + HDAd-SB at the indicated MOIs per virus and subjected to CFU assays. Shown is the mean ± SD percentage of 
GFP+ colonies 14 days after plating. 
Supplementary Methods 
 
Adenovirus vectors: 
First-generation Ad5/35++-GFP and Ad5-GFP vectors: These Ad5-based vectors are deleted for the E1 and 
E3 regions and contained a 2.3-kb cytomegalovirus promoter-driven enhanced green fluorescent protein 
(EGFP) gene (derived from pEGFP-1) (Clontech, Palo Alto, CA) inserted into the E3 region. The Ad5/35++ 
vector contained, the short Ad35 fiber shaft and the Ad35 fiber knob with Asp207Gly and Thr245Ala amino 
acid substitutions instead of the Ad5 shaft and knob 1.  
HDAd-GFP: Generation of the transposon vector HDAd-GFP: The plasmid pHM5-attB-TMCS-FRT2 was 
described earlier 2. It was modified by adding a PacI linker into the PmeI restriction enzyme site. The 
expression cassette encoding GFP under the control of the elongation factor alpha-1 (EF1α) promoter was 
released from the plasmid pEf1a-GFP by PacI restriction enzyme digest and ligated into the plasmid pHM5-
attB-TMCS-FRT2 resulting into the intermediate clone pHM5-T/EF1α-GFP-FRT2. The bacterial artificial 
chromosome (BAC) containing the helper-dependent Ad5 genome (B-HCA) was described earlier 3. Based 
on our previously established recombineering pipeline 3, we inserted a selection marker flanked by 
homology arms into the BAC B-HCA and then replaced it by the transposon encoding GFP under the 
control of the EF1α promoter flanked by FRT sites. For recombineering, the transposon was released 
through the restriction enzymes I-CeuI and PI-SceI and recombined into the BAC. The new recombineering 
protocol is involves the selection marker galK which can be used for positive and negative selection. In 
this system, recombinases are encoded endogenously by bacteria of E. coli strain SW102, which express 
high levels upon heat-induction. In contrast to previous methods, small homologous regions (<50 bp) are 
sufficient for efficient recombination, which can be generated by PCR utilizing adequate primers.  
HDAd-SB: The vector expressing the hyperactive SB100x has been described recently 4. In brief, the Flp 
recombinase expression cassette consisting of the Ef1a promotor, the Flp recombinase cDNA and the 
polyA signal was PCR amplified from plasmid pFTCHSB5- Flp was used. The PCR product was cloned into 
the plasmid pHM5-PmeI using the restriction enzyme PmeI resulting in the plasmid pHM5-Flp 5. 
Subsequently the cDNA of SB100X was PCR amplified from pZac-SB100 and the fragment was cloned into 
the PmeI site of pPGK-TP. The SB100X expression cassette expressed under control of the PGK promoter 
was PCR amplified and cloned into pHM5- FLP, resulting in the plasmid pHM5-Flp-SB100. After ClaI digest 
of this plasmid, homologous arms flanking the Flp-SB100 cassette for subsequent recombinieering into 
pBHCA-galK-kan3 harboring the adenoviral 5ITR, the adenoviral packing signal Ψ, and the 3'ITR were 
generated by PCR using primers BHCA-Pepi-5 This PCR fragment was then inserted via galK basedcounter-
selection recombineering into pBHCA-galK-kan43 replacing galK-Kan with the Flp-SB100 cassette. 
HD-Ad5/35++ vector production: For the production of HDAd-SB and HDAd-GFP virus, corresponding 
plasmids were linearized with PmeI and rescued in 116 cells 6 with AdNG163-5/35++, an Ad5/35++ helper 
vector containing chimeric fibers composed of the Ad5 fiber tail, the Ad35 fiber shaft, and the affinity-
enhanced Ad35++ fiber knob. AdNG163-5/35++ was constructed by replacing the 2,015 bp NdeI-AflII 
fragment from pAdNG163-2 7 with the 1,259 bp NdeI-AflII fragment from pWE15-A2 1. HD-Ad5/35++ 
vectors were produced in 116 cells as described in detail elsewhere 6. In brief, the liberated HD-Ad genome 
is transfected into 116 cells expressing Cre recombinase and and infected with the helper virus bearing a 
packaging signal flanked by loxP sites. Cre-mediated excision of the packaging signal renders the helper 
virus genome unpackagable, but still able to replicate and provide all of the necessary trans-acting factors 
for propagation of the HDAd. The titer of the HDAd is increased by serial passages on 116 cells. Finally, 
the HDAd is purified by CsCl ultracentrifugation. Helper virus contamination levels were found to be 
<0.05%. Titers were 3-9x1012 vp/ml. 
 
Cells: CD34+ cells were recovered from frozen stocks and incubated overnight in Iscove’s modified 
Dulbecco’s medium (IMDM) supplemented with 10% heat-inactivated FCS, 1% BSA 0.1 mmol/l 2-
mercaptoethanol, 4 mmol/l glutamine and penicillin/streptomycin, Flt3 ligand (Flt3L, 50 ng/ml), 
interleukin 3 (20 ng/ml), thrombopoietin, (10 ng/ml) and stem cell factor (50 ng/ml). Cytokines and growth 
factors were obtained from Peprot were maintained in RPMI 1640 medium containing 10% FCS, 2 mmol/l 
l-glutamine, Pen-Strep, and granulocyte-macrophage colony stimulating factor (GM-CSF, 0.1 ng/ml) 
(Peprotech, Rocky Hill, NJ). 
 
Flow cytometry: For flow analysis of LSK cells, cells were treated with FcR blocking reagent (Miltenyi 
Biotec, San Diego, CA), stained with  biotin-conjugated lineage detection cocktail (Miltenyi Biotec, San 
Diego, CA) and antibodies against c-Kit and Sca-1 as well as APC-conjugated streptavidin. Other antibodies 
including anti-mouse-CD3, -CD11b, -CD19, Gr-1, -CD48, -CD150 as well as anti-human-CD3, -CD19, -CD33, 
-CD45 and –CD46 were from BD Biosciences (Franklin Lakes, NJ) or eBioscience (San Diego, CA). 
 
Colony-forming unit (CFU) assay: CFU assays were performed using ColonyGEL (Reachbio, Seattle, WA) 
human or mouse complete medium to the manufacturer’s specifications. For CFU assays of in vivo 
transduced hCD46tg animals, bone marrow cells were isolated aseptically and lineage-depleted using the 
mouse lineage depletion kit (Miltenyi Biotec, San Diego, CA). Cells were then sorted for GFP+ using FACS 
and subjected to CFU assays. Colonies were scored 12 days after plating.  
 
Integration analysis in MO7e cells: MO7e cells were infected either with HDAd-GFP alone or with a 1:1 
mixture of HDAd-SB and HDAd-GFP. Cells were cultured for 48 h to allow for transgene expression. GFP+ 
cells were sorted into 96-well plates using FACS at 1 cell per well. The single clones were expanded for 2 
weeks and the percentage of GFP+ cells per colony was assessed visually using a UV microscope. Clones 
with the highest expression levels of GFP were selected and further expanded for integration analysis by 
Southern Blot. For this, genomic DNA of selected clones was isolated and digested with SacI. If integration 
of the viral genome occurred at random the digest would result in a GFP-containing fragment of 2500 bp. 
If the integration of the GFP cassette was mediated by the Sleeping Beauty transposase, GFP fragments 
of varying sizes would be obtained. Digested gDNA was analyzed by Southern blotting as described before 
8 and detected with a CTP-labeled GFP probe. The 720 bp probe was obtained by digesting a plasmid 
containing the viral GFP cassette with NcoI and NotI. No specific feature within images shown in 
supplemental figure S2 was enhanced, obscured, moved, removed, or introduced. 
 
qPCR for Ad genomes: Tissues were collected, and homogenized using a TissueRuptor (Qiagen, Valencia, 
CA). From the tissue samples, genomic DNA (gDNA) was isolated using the Blood and Tissue Kit (Qiagen, 
Valencia, CA) to the manufacturer’s instructions and gDNA concentration was determined 
spectrophotometrically. gDNA samples were analyzed for vector genomes carrying a GFP cassette with 
the following primers: FWD: TCGTGACCACCCTGACCTAC, REV: GGTCTTGTAGTTGCCGTCGT. qPCR was 
performed using the Kapa SYBR Fast qPCR Kit master mix (Kapa Biosystems, Boston, MA). Each reaction 
was run in triplicates. Serial dilutions of purified HDAd-GFP viral DNA were used as a standard curve. 
 
Tissue immunofluorescence analysis: Before tissue harvest, blood was flushed from the circulation with 
PBS using the heart as a pump. Tissues were frozen in OCT compound. Sections (6 m) were fixed in 4% 
para-formaldehyde and either remained unstained or were stained with rat anti-mouse CD45 primary Ab 
(BD Biosciences, Franklin Lakes, NJ). Specific binding of primary Abs was visualized with secondary anti-
rat Alexa Fluor 488 Ab. After washing, the slides were mounted with Vectashield containing DAPI (Vector 
Laboratories, Inc. Burlingame CA). Immunofluorescence microphotographs were taken at room 
temperature on a Leica DMLB microscope (40x oil lens) (Leica, Wetzlar, Germany) with a Leica DFC300FX 
digital camera and Leica Application Suite Version 2.4.1 R1 (Leica Microsystems, Heerbrugg, Switzerland). 
No specific feature within images shown in supplemental figure S6 was enhanced, obscured, moved, 
removed, or introduced. 
 
Construction of integration site libraries for Illumina sequencing: Amplification of SB genomic DNA 
junctions was performed by linear amplification-mediated PCR as described previously 9 with some 
modifications. Genomic DNA was isolated from GFP+ hCD46tg colonies using the DNeasy Blood and Tissue 
kit (Qiagen, Valencia, CA). These CFU colonies were obtained from lin-/GFP+ bone marrow cells of in vivo 
transduced hCD46tg animals as described below. The isolated genomic DNA was digested with NlaIII or 
MluCI restriction enzymes and ligated to adaptors having NlaIII (annealed NlaIII+ and NlaIII- linkers) or 
MluCI (annealed MluCI+ and MluCI- linkers) compatible overhangs. Then 2 X 50 rounds of linear 
amplification was carried out with a biotinylated SB left inverted repeat specific primer (LAM SB-50-Bio) 
to enrich fragments with SB genomic junction. The single-stranded biotinylated products were captured 
on streptavidin-coated magnetic beads using Dynabeads kilobase BINDER kit (Invitrogen, Carlsbad, CA). 
After washing the beads with water, the captured products were eluted in water by incubating at 80 °C 
for 3 min, and used as template of nested PCRs. During amplification, we used bar-coded primers specific 
for the SB left inverted repeat and adapter specific primers so that we could pool different libraries in the 
subsequent steps (primers in PCR1: linker primer and SB-20-hmr-bio; primers inPCR2: nested primer and 
SB_PE_new_bc1 or bc2 or bc3). Finally, primers corresponding to Illumina adapter sequences were used 
(PE_nest_ind1 and Illumina1) to yield a directional library, in which sequences complementary to the 
Illumina genomic DNA sequences primer were located upstream to the SB left inverted repeat. The 
resulting libraries were pooled and sequenced on a single flow cell lane on Illumina HiSeq Genome 
Analyzer platform with rapid 1X100 bp single end run settings. 
 
Linker 
forming 
Oligo name sequence 
MluCI+ PE_Linker(+) gtaatacgactcactatagggctccgcttaagggacgtgactggagttcagacgtgtgctcttccgatct 
NlaIII+ PE_NlaIII_Linker(+) gtaatacgactcactatagggctccgcttaagggacgtgactggagttcagacgtgtgctcttccgatctcatg 
NlaIII- PE_Linker(-)blunt agatcggaagagcacacgtctgaactccagtcac-amino 
MluCI- PE_Linker(-)MluCI aattagatcggaagagcacacgtctgaactccagtcac-amino 
 
LAM SB-50-Bio bio-agttttaatgactccaacttaagtg 
Linker Primer Gtaatacgactcactatagggc 
SB-20hmr-Bio bio-aacttaagtgtatgtaaacttccgact 
Nested Primer Agggctccgcttaagggac 
SB_PE_new_bc1  acactctttccctacacgacgctcttccgatctatcacggtatgtaaacttccgacttcaa 
SB_PE_new_bc2 acactctttccctacacgacgctcttccgatctacatcggtatgtaaacttccgacttcaa 
SB_PE_new_bc3 acactctttccctacacgacgctcttccgatctgcctaagtatgtaaacttccgacttcaa 
PE_nest_ind1 caagcagaagacggcatacgagatcgtgatgtgactggagttcagacgtgtgctcttccgatct 
Illumina 1 aatgatacggcgaccaccgagatctacactctttccctacacgacgctcttccgatct 
 
 
Bioinformatic Analysis of Integration Sites: Sample-specific barcoded sequencing reads were de-
multiplexed from multiplexed flow cells using CASAVA, an Illumina software suit. The quality of 
sequencing runs of resulting fastq files was evaluated using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Reads were starting with the barcode 
GTATGTAAACTTCCGACTTCAACTG that follows the TA dinucleotide which is characteristic of SB integration 
were aligned against the latest version of mouse reference genome (GRCm38/mm10 (Dec, 2011)), using 
bowtie 10. Distribution of integrations: Annotations of UTRs, Exons and CDS were downloaded from 
https://genome.ucsc.edu/cgi-bin/hgTables. We further extended the coordinated in silico to annotate 
them as shown in Fig.3f. We analyzed the percentage of integration sites overlapping with the given 
genomic coordinates. Analysis for Randomness: We performed the Bartels rank test of randomness upon 
the position of integration sites. This test displayed a p-value of < 2.2e-15. When we performed the same 
test on the distance between any two given integrations, it displayed a p-value = 0.02636 suggesting 72 
percent of randomness. To create Fig.3h, we indexed and created 400 normal, shuffled and randomized 
windows of mouse genome mm10 using BEDtools 11. We then counted the number of integrations for 
each window and plotted the density. Integration into or near cancer-related genes: Genes from pathways 
in cancer - Mus musculus (mouse) were downloaded from KEGG database (http://www.genome.jp/kegg-
bin/show_pathway?mmu05200). We mapped their genomic coordinates and calculated the distance of 
integration sites from the closest cancer-related genes. 
 
Animal studies: All experiments involving animals were conducted in accordance with the institutional 
guidelines set forth by the University of Washington. 
 
anti-GFP antibody ELISA: Plates were coated with recombinant GFP (Clontech) (0.3g per well in 0.1M 
Na-bicarbonate buffer pH9.6, o/n at 4oC). After blocking in Starting Block PBS buffer (Thermo Scientific), 
plates were incubated with mouse serum dilution (1:1000 in blocking buffer) followed by anti-mouse Ig-
HRP conjugate. OD450 was measured and used to express antibody titers.   
 
anti-GFP T-cell assay: CD8 T-cell responses in splenocytes harvested from mice 20 weeks after in vivo HSC 
transduction. For in vitro stimulation, splenocytes from naïve hCD46 transgenic mice (C57Bl/6 
background) were transduced with HDAd-GFP (AdGFP) or an HD-Ad control (AdCo) virus (without GFP) at 
an MOI of 1000 vp/cell, or mock-transdcued, and cultured for three days. For the T-cell assay, cells were 
irradiated at 2500 Rad. Splenocytes from in vivo transduced mice (N=4) and one naïve mouse were 
harvested 20 weeks after transduction. CD8 cells were isolated using the Miltenyi MACS isolation kit. 
These cells were mixed with stimulator cells at a ratio of 5:1 and incubated for 5 days in the presence of 
10U/ml IL-2. To measure GFP-specific T-cell activation (IFN production), C57Bl/6 derived TC1 cancer cells 
were transduced with HDAd-GFP or HDAd-Co and incubated for 3 days (designated “TC1-AdCo” and “TC1-
AdGFP” target cells in the figure). Target cells were incubated with in vitro stimulated CD8 cells at a ratio 
of 1:1 and IFN levels in the supernatants were measured by ELISA (eBioscience) 24 hours later. 
 
Blood analyses: Blood cell counts and blood chemistry analyses were performed by the University of 
Washington Medical Center laboratories. Serum levels of inflammatory cytokines were analyzed a Mouse 
Inflammatory Cytometric Bead Array (BD Biosciences, Franklin Lakes, NJ). 
 
Statistical analyses: For the statistical comparison of two groups unpaired, two-sided T-tests were used. 
If the group variances were significantly different, Welch's correction was employed. For comparisons of 
multiple groups, one-way and two-way analysis of variance (ANOVA) with Bonferroni post-testing for 
multiple comparisons was employed. Statistical analysis was performed using GraphPad Prism version 
6.01 (GraphPad Software Inc., La Jolla, CA). * P < .05; ** P < .01; *** P < .001, **** P < .0001 
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